BioSpace News Archive

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy ® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.

Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY).

Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology, announced the launch of the Kodiak™ Dual Port Coaxial Introducer Kit for precise and streamlined introduction of diagnostic and therapeutic devices into the vasculature.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company’s founder, president and CEO, will present virtually on December 5, 2023 at the MedInvest Oncology Investor Conference.

Scilex Holding Company announced the successful completion of a Good Manufacturing Practices inspection by the U.S. Food and Drug Administration of the enhanced manufacturing facility of Oishi Koseido Co., Ltd. for ZTlido® located in Tosu, Saga, Japan.

Artelo Biosciences, Inc. today announced George Warren, PhD., Principal Scientist at Artelo Biosciences, will be presenting new preclinical data on ART12.11.

Clarity Pharmaceuticals is pleased to announce that the first patient ever to be dosed with two cycles of 8GBq of 67Cu-SAR-bisPSMA has had a drop in PSA to undetectable levels, undetectable disease using PET and a near complete response to treatment under RECIST.

Gilgamesh Pharmaceuticals announces the successful completion of its Phase 1 Single Ascending Dose (SAD) trial of GM-2505, a novel 5-HT2A receptor agonist.

Shuttle Pharmaceuticals Holdings, Inc. today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will be participating in the Emerging Growth Conference on December 7, 2023 (the “Conference”).

Adela, Inc. is presenting data today demonstrating the feasibility of using its platform for cfDNA cancer signal quantification and prognostic prediction in early stage non-small cell lung cancer (NSCLC), during the Plenary Abstract Session at the 2023 Multidisciplinary Thoracic Cancers Symposium in New Orleans.